Price
CHART BY
Frequently asked questions
What is Exelixis's market capitalization?
The market capitalization of Exelixis is $14.01B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Exelixis's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Exelixis is 17.76. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Exelixis?
Exelixis's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $3.184. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Exelixis's stock?
Currently, 21 analysts cover Exelixis's stock, with a consensus target price of $53.69. Analyst ratings provide insights into the stock's expected performance.
What is Exelixis's revenue over the trailing twelve months?
Over the trailing twelve months, Exelixis reported a revenue of $2.44B.
What is the EBITDA for Exelixis?
Exelixis's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $1.02B. EBITDA measures the company's overall financial performance.
What is the free cash flow of Exelixis?
Exelixis has a free cash flow of $1.17B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Exelixis have, and what sector and industry does it belong to?
Exelixis employs approximately 1,077 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Exelixis's shares?
The free float of Exelixis is 239.91M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $14.01B
- EPS (TTM)
- $3.184
- Free Float
- 239.91M
- P/E ratio (TTM)
- 17.76
- Revenue (TTM)
- $2.44B
- EBITDA (TTM)
- $1.02B
- Free Cashflow (TTM)
- $1.17B
Pricing
- 1D span
- $55.27$56.46
- 52W span
- $33.76$59.71
Analyst Ratings
The price target is $53.69 and the stock is covered by 21 analysts.
Buy
7
Hold
12
Sell
2
Information
Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.
- Employees
- 1,077
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- EXEL
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet